Insitro

Series CBiotechnologyprivate

Machine learning-driven drug discovery company using large-scale data generation and AI to identify new therapeutics.

Valuation
$2B
Total Funding
$643M
Stage
Series C
Sector
Biotechnology
Headquarters
South San Francisco, CA
CEO
Daphne Koller
IPO Status
private

Funding History

Round Amount Date
Series C $400M Sep 2022
Series B $143M Dec 2020
Series A $100M Jul 2019

Track Insitro IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO โ€” the pre-IPO intelligence platform.

Loading company data...